Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Prognostic factors and survival of recurrent glioblastoma: a systematic review
View through CrossRef
Introduction: Glioblastoma is a highly aggressive brain cancer with poor prognosis. Recurrence is common, and survival post-recurrence is limited. Identifying prognostic factors for recurrent glioblastoma can optimize treatment and improve outcomes.
Aim: This systematic review analyzed the clinical, molecular, and treatment-related variables that influence survival in patients with recurrent glioblastoma.
Materials and methods: A comprehensive search of PubMed, Scopus, and ProQuest databases included studies from the past decade, assessed using the Newcastle-Ottawa Scale (NOS).
Results: Sixteen studies were analyzed, highlighting age, Karnofsky Performance Status (KPS), molecular markers (MGMT promoter methylation, IDH mutations, TERT promoter mutations, TP53 alterations, ATRX loss, and Ki-67 expression), and surgical resection extent as key prognostic factors. Younger patients with higher KPS scores and favorable molecular markers had better survival. Molecular profiling and maximal resection correlated with improved overall survival (OS). Salvage therapies like chemotherapy and re-resection provided marginal benefits, with variability based on patient demographics and tumor genetics.
Conclusion: Age, KPS, molecular markers, and surgical resection extent significantly predict survival in recurrent glioblastoma. The review underscores the importance of molecular profiling for personalized treatment, though current salvage therapies show limited effectiveness. Innovative approaches are needed to enhance outcomes for this aggressive disease.
Abbreviations used in the article: BSC: best supportive care; CRE: complete resection of enhancing tumor; DFS: disease-free survival; GBM: glioblastoma; GTR: gross total resection; KPS: Karnofsky Performance Status; NOS: Newcastle-Ottawa Scale; OS: overall survival; PFS: progression-free survival; rGBM: recurrent glioblastoma multiforme; RTOG–RPA: Radiation Therapy Oncology Group – Recursive Partitioning Analysis; TTF: tumor-treating fields
Pensoft Publishers
Title: Prognostic factors and survival of recurrent glioblastoma: a systematic review
Description:
Introduction: Glioblastoma is a highly aggressive brain cancer with poor prognosis.
Recurrence is common, and survival post-recurrence is limited.
Identifying prognostic factors for recurrent glioblastoma can optimize treatment and improve outcomes.
Aim: This systematic review analyzed the clinical, molecular, and treatment-related variables that influence survival in patients with recurrent glioblastoma.
Materials and methods: A comprehensive search of PubMed, Scopus, and ProQuest databases included studies from the past decade, assessed using the Newcastle-Ottawa Scale (NOS).
Results: Sixteen studies were analyzed, highlighting age, Karnofsky Performance Status (KPS), molecular markers (MGMT promoter methylation, IDH mutations, TERT promoter mutations, TP53 alterations, ATRX loss, and Ki-67 expression), and surgical resection extent as key prognostic factors.
Younger patients with higher KPS scores and favorable molecular markers had better survival.
Molecular profiling and maximal resection correlated with improved overall survival (OS).
Salvage therapies like chemotherapy and re-resection provided marginal benefits, with variability based on patient demographics and tumor genetics.
Conclusion: Age, KPS, molecular markers, and surgical resection extent significantly predict survival in recurrent glioblastoma.
The review underscores the importance of molecular profiling for personalized treatment, though current salvage therapies show limited effectiveness.
Innovative approaches are needed to enhance outcomes for this aggressive disease.
Abbreviations used in the article: BSC: best supportive care; CRE: complete resection of enhancing tumor; DFS: disease-free survival; GBM: glioblastoma; GTR: gross total resection; KPS: Karnofsky Performance Status; NOS: Newcastle-Ottawa Scale; OS: overall survival; PFS: progression-free survival; rGBM: recurrent glioblastoma multiforme; RTOG–RPA: Radiation Therapy Oncology Group – Recursive Partitioning Analysis; TTF: tumor-treating fields.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract 1842: Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Abstract
Background: The standard therapy for glioblastoma patients is tumor resection followed by radiotherapy and temozolomide chemotherapy. Although glioblastoma ...
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Abstract
Introduction: Gliosarcoma (GSM) is a rare, aggressive primary CNS tumor and a histopathological variant of glioblastoma, characterized by both glial and sarcomatou...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
High-dose Salvage Re-irradiation in Recurrent/progressive Adult Diffuse High-Grade Glioma: Development of a Novel Prognostic Scoring System
High-dose Salvage Re-irradiation in Recurrent/progressive Adult Diffuse High-Grade Glioma: Development of a Novel Prognostic Scoring System
Abstract
Purpose: Over the past two decades, high-dose salvage re-irradiation (re-RT) has been used increasingly in the multimodality management of adults with recurrent/pr...
EMP3 as a prognostic biomarker correlates with EMT in GBM
EMP3 as a prognostic biomarker correlates with EMT in GBM
Abstract
Background: Glioblastoma (GBM) is the most aggressive malignant central nervous system tumor with a poor prognosis.The malignant transformation of glioma cells via...